

# Charles L Bennett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6532831/publications.pdf>

Version: 2024-02-01

173  
papers

8,432  
citations

126708

33  
h-index

45213

90  
g-index

174  
all docs

174  
docs citations

174  
times ranked

8625  
citing authors

#	ARTICLE	IF	CITATIONS
1	Medicare Spending on Drugs With Accelerated Approval. <i>Annals of Internal Medicine</i> , 2022, 175, 938-944.	2.0	7
2	Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997â€“2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). <i>EClinicalMedicine</i> , 2021, 31, 100693.	3.2	3
3	Do radiation oncologists and urologists endorse decision aids for active surveillance of lowâ€“risk prostate cancer: Results from a national survey. <i>European Journal of Cancer Care</i> , 2021, 30, e13301.	0.7	0
4	Cytoplasmic synthesis of endogenous <i>Alu</i> complementary DNA via reverse transcription and implications in age-related macular degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	36
5	The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. <i>Oncologist</i> , 2021, 26, e1418-e1426.	1.9	1
6	Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 1274-1305.	0.8	67
7	Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate controlling for age, sex and cancer type. <i>BMJ Health and Care Informatics</i> , 2021, 28, e100341.	1.4	12
8	A spatial assessment of prostate cancer mortality-to-incidence ratios among South Carolina veterans: 1999â€“2015. <i>Annals of Epidemiology</i> , 2021, 59, 24-32.	0.9	0
9	Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. <i>Lancet Haematology</i> , the, 2021, 8, e593-e604.	2.2	26
10	Four-Fold Increased Mortality from Sars-Cov-2 Infection in Patients with Hematologic Versus Non-Hematologic Malignancies Treated at the Largest Tertiary COVID-19 Center in Chicago/Rush University Medical Center (March 1, 2020-December 31,2020). <i>Blood</i> , 2021, 138, 1947-1947.	0.6	1
11	A New Criterion for Fluoroquinolone-Associated Disability Diagnosis: Functional Gastrointestinal Disorders. <i>Medicina (Lithuania)</i> , 2021, 57, 1371.	0.8	3
12	End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. <i>PLoS ONE</i> , 2020, 15, e0234541.	1.1	4
13	Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. <i>Lancet Oncology</i> , The, 2020, 21, e575-e588.	5.1	15
14	Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development. <i>Nature Communications</i> , 2020, 11, 4737.	5.8	31
15	Response to: letter to the editor: consideration on an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agencyâ€™ by bennett et al. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1057-1057.	1.0	0
16	End of an era for erythropoiesisâ€“stimulating agents in oncology. <i>International Journal of Cancer</i> , 2020, 146, 2829-2835.	2.3	8
17	Patient- and area-level predictors of prostate cancer among South Carolina veterans: a spatial analysis. <i>Cancer Causes and Control</i> , 2020, 31, 209-220.	0.8	6
18	Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. <i>PLoS ONE</i> , 2019, 14, e0219521.	1.1	5

#	ARTICLE	IF	CITATIONS
19	An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1055-1063.	1.0	58
20	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2099-2108.	1.2	4
21	Failure to place evidence at the centre of quality improvement remains a major barrier for advances in quality improvement. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 369-372.	0.9	11
22	Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. <i>Cancer Medicine</i> , 2019, 8, 2233-2240.	1.3	8
23	Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. <i>Oncologist</i> , 2019, 24, 537-548.	1.9	17
24	A unifying framework for improving health care. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 358-362.	0.9	21
25	Biosimilar Filgrastim Use in the United States vs the European Union and Japan—Why Does It Lag Behind and What Can Be Done?. <i>JAMA Oncology</i> , 2019, 5, 297.	3.4	8
26	EDITORIAL COMMENT. <i>Urology</i> , 2019, 123, 119.	0.5	0
27	Editorial Comment. <i>Urology</i> , 2018, 113, 144-145.	0.5	0
28	Progressive multifocal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 301-304.	1.2	16
29	Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition. <i>Drugs</i> , 2018, 78, 1777-1781.	4.9	37
30	Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents. <i>American Journal of Therapeutics</i> , 2018, 25, e670-e674.	0.5	2
31	Fluoroquinolone-associated suicide. <i>European Journal of Internal Medicine</i> , 2018, 55, e21-e22.	1.0	12
32	Editorial Comment. <i>Urology</i> , 2018, 118, 125-126.	0.5	0
33	Trends of Palliative Care Utilization in Acute Myeloid Leukemia in the United States. <i>Blood</i> , 2018, 132, 4767-4767.	0.6	1
34	Improving the Evidence Base for Delivery of High-Quality Cancer Care. <i>JAMA Oncology</i> , 2017, 3, 1029.	3.4	4
35	Generic drugs in oncology — Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e64.	5.1	0
36	Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions. <i>Transfusion</i> , 2017, 57, 2045-2053.	0.8	5

#	ARTICLE	IF	CITATIONS
37	What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e977-e985.	0.9	4
38	Biosimilarsâ€™ Curb Your Enthusiasm. <i>JAMA Oncology</i> , 2017, 3, 1467.	3.4	15
39	Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. <i>Lancet Oncology</i> , The, 2017, 18, 22-23.	5.1	7
40	Challenges to Biosimilar Substitution. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1186.	3.8	9
41	Editorial Comment. <i>Urology</i> , 2017, 109, 16-17.	0.5	0
42	Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). <i>Cancer Medicine</i> , 2017, 6, 1541-1551.	1.3	24
43	Types of oral contraceptives and breast cancer survival among women enrolled in Medicaid: A competing-risk model. <i>Maturitas</i> , 2017, 95, 42-49.	1.0	4
44	Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. <i>Journal of Clinical Oncology</i> , 2017, 35, 1945-1951.	0.8	16
45	Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. <i>Journal of Oncology Practice</i> , 2017, 13, e562-e573.	2.5	9
46	Opioid Prescription Drug Use and Expenditures in US Outpatient Physician Offices: Evidence from Two Nationally Representative Surveys. <i>Cancer Therapy &amp; Oncology International Journal</i> , 2017, 3, .	0.1	3
47	Assessing Colorectal Cancer Screening Adherence of Medicare Fee-for-Service Beneficiaries Age 76 to 95 Years. <i>Journal of Oncology Practice</i> , 2016, 12, e670-e680.	2.5	10
48	Editorial Comment. <i>Urology</i> , 2016, 94, 15-16.	0.5	0
49	Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. <i>Leukemia Research</i> , 2016, 44, 61-64.	0.4	25
50	Thrombotic thrombocytopenic purpura: gaining knowledge. <i>Lancet Haematology</i> , the, 2016, 3, e210-e211.	2.2	3
51	Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 193-200.	1.1	5
52	Big data, thromboembolism, and immunoglobulin. <i>Blood</i> , 2016, 127, 171-172.	0.6	1
53	Relationship of Industry Sponsorship to Results of Cost-Effectiveness Analyses of Drugs Used in Breast Cancer Treatmentâ€™Reply. <i>JAMA Oncology</i> , 2016, 2, 549.	3.4	0
54	Peginesatide for the treatment of anemia due to chronic kidney disease â€™ an unfulfilled promise. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1421-1426.	1.0	33

#	ARTICLE	IF	CITATIONS
55	Cardiovascular disease incidence among females in South Carolina by type of oral contraceptives, 2000-2013: a retrospective cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 991-997.	0.8	7
56	Generic oncology drugs: are they all safe?. <i>Lancet Oncology</i> , The, 2016, 17, e493-e501.	5.1	33
57	Editorial Comment. <i>Urology</i> , 2016, 93, 74-75.	0.5	0
58	Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1003-1011.	1.0	76
59	Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment. <i>JAMA Oncology</i> , 2016, 2, 274.	3.4	9
60	Progestin and breast cancer risk: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 3-12.	1.1	61
61	Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. <i>JAMA Oncology</i> , 2016, 2, 134.	3.4	15
62	Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 54-65.	0.1	32
63	Petitioning the FDA to Improve Pharmaceutical, Device and Public Health Safety by Ordinary Citizens: A Descriptive Analysis. <i>PLoS ONE</i> , 2016, 11, e0155259.	1.1	5
64	Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. <i>Transfusion</i> , 2015, 55, 2321-2330.	0.8	19
65	Editorial Comment. <i>Urology</i> , 2015, 85, 413.	0.5	2
66	Population-Based Assessment of Determining Treatments for Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 67.	3.4	0
67	Economics of Malignant Gliomas: A Critical Review. <i>Journal of Oncology Practice</i> , 2015, 11, e59-e65.	2.5	46
68	Japanese regulatory authority's perspective on biosimilars - Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e102.	5.1	0
69	STEC:O111:HUS complicated by acute encephalopathy in a young girl was successfully treated with a set of hemodiafiltration, steroid pulse, and soluble thrombomodulin under plasma exchange. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 208-212.	0.2	8
70	Editorial Comment. <i>Urology</i> , 2015, 86, 78.	0.5	0
71	Adding Bevacizumab to the Treatment of Patients With Non-Small-Cell Lung Cancer: Caveat Emptor. <i>Journal of Oncology Practice</i> , 2015, 11, 363-364.	2.5	2
72	Editorial Comment. <i>Urology</i> , 2015, 85, 153-154.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Systematic Approach to Pharmacovigilance beyond the Limits: The Southern Network on Adverse Reactions (SONAR) Projects. <i>Advances in Pharmacoepidemiology &amp; Drug Safety</i> , 2014, 3, .	0.1	2
74	Financial burden experienced by patients undergoing treatment for malignant gliomas. <i>Neuro-Oncology Practice</i> , 2014, 1, 71-76.	1.0	9
75	Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. <i>Cancer</i> , 2014, 120, 4006-4007.	2.0	1
76	Anaphylaxis and Hypotension after Administration of Peginesatide. <i>New England Journal of Medicine</i> , 2014, 370, 2055-2056.	13.9	53
77	Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. <i>Cancer</i> , 2014, 120, 2464-2471.	2.0	113
78	Regulatory and clinical considerations for biosimilar oncology drugs. <i>Lancet Oncology</i> , The, 2014, 15, e594-e605.	5.1	99
79	Toxicity and Costs of Toxicity Associated With New Cancer Drugs: International Implications. <i>Journal of Clinical Oncology</i> , 2014, 32, 3591-3592.	0.8	11
80	Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 26.e25-26.e31.	0.8	2
81	Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus. <i>Wound Repair and Regeneration</i> , 2014, 22, 23-33.	1.5	62
82	Editorial Comment. <i>Urology</i> , 2014, 84, 1072.	0.5	0
83	Editorial Comment. <i>Urology</i> , 2014, 83, 786-787.	0.5	0
84	Attention must be paid: adverse event reporting needs improvement. <i>Clinical Investigation</i> , 2014, 4, 5-7.	0.0	0
85	The Reduction of Erythropoietin Stimulating Agent (ESA) Use Due to the FDA Black Box Warning. <i>Blood</i> , 2014, 124, 1276-1276.	0.6	2
86	Introduction of a Quick Assay for ADAMTS13 Activity Improved a Survival of Acquired TTP Patients Who Received Platelet Transfusions. <i>Blood</i> , 2014, 124, 4209-4209.	0.6	2
87	Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012). <i>Blood</i> , 2014, 124, 4456-4456.	0.6	2
88	Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy. <i>New England Journal of Medicine</i> , 2013, 368, 1131-1139.	13.9	140
89	Colony-Stimulating Factors for Febrile Neutropenia. <i>New England Journal of Medicine</i> , 2013, 369, 284-286.	13.9	2
90	Primary Prophylaxis With Hematopoietic Colony Stimulating Factor: Insights From a Canadian Cost-Effectiveness Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1072-1073.	3.0	3

#	ARTICLE	IF	CITATIONS
91	Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). <i>British Journal of Haematology</i> , 2013, 161, 896-898.	1.2	23
92	Rituximab and biosimilars – equivalence and reciprocity. <i>Biosimilars (Auckland, New Zealand)</i> , 2013, 2013, 19.	0.4	23
93	Fatal and Serious Anaphylaxis Following Peginesatide Administration. <i>Blood</i> , 2013, 122, 5612-5612.	0.6	0
94	Conflicts Of Interest In Pharmaceutical Sponsored Research On Erythropoietin Receptors In Cancer: An Updated Analysis. <i>Blood</i> , 2013, 122, 2938-2938.	0.6	0
95	Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 905-907.	1.5	28
96	Adverse Effects of Drugs on Hemostasis and Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 755-758.	1.5	1
97	A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR). <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 783-796.	1.5	32
98	Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR). <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 845-853.	1.5	77
99	A 56-Year-Old Physician Who Underwent a PSA Test. <i>Archives of Internal Medicine</i> , 2012, 172, 311.	4.3	26
100	Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 82-88.	1.4	79
101	Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye's Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR). <i>Journal of General Internal Medicine</i> , 2012, 27, 1697-1703.	1.3	31
102	Epidemiologic Methods Lessons Learned from Environmental Public Health Disasters: Chernobyl, the World Trade Center, Bhopal, and Graniteville, South Carolina. <i>International Journal of Environmental Research and Public Health</i> , 2012, 9, 2894-2909.	1.2	22
103	First Estimates of Incidence of Progressive Multifocal Leukoencephalopathy Developing Among 10,459 Non-HIV Lymphoma VA Patients Who Receive Rituximab: Results From the Veterans Administration Database (1999–2012). <i>Blood</i> , 2012, 120, 2752-2752.	0.6	0
104	Evaluating Conflicts of Interest in Academic Research On Erythropoietin Receptors in the Cancer Setting. <i>Blood</i> , 2012, 120, 4695-4695.	0.6	0
105	Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000. <i>Blood</i> , 2012, 120, 2203-2203.	0.6	3
106	Cocaine-Levamisole Thrombovasculopathy: A Report From the Southern Network On Adverse Reactions (SONAR) Project. <i>Blood</i> , 2012, 120, 3403-3403.	0.6	0
107	Anti-ADAMTS13 Inhibitor Boosting During Plasma Exchange Therapy Often Causes an Intractable Acquired Idiopathic TTP. <i>Blood</i> , 2012, 120, 1086-1086.	0.6	1
108	Why Is Cancer Care So Expensive: Potential Implications of Fraud and Abuse. <i>Blood</i> , 2012, 120, 4275-4275.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Pharmacovigilance and PML in the oncology setting. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, S13-S17.	0.6	13
110	Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A Twenty Year Review. <i>Blood</i> , 2011, 118, 2226-2226.	0.6	1
111	Translating Research Into Policy: A Review of Pharmacovigilance Efforts From the Southern Network On Adverse Reactions (SONAR) Group. <i>Blood</i> , 2011, 118, 4756-4756.	0.6	0
112	The Importance of Press Releases Describing ASH Conference Findings in Translating Research Into Policy: Case Study and Seven-Year Follow-up From a 2004 Oral Presentation. <i>Blood</i> , 2011, 118, 4766-4766.	0.6	0
113	Location, Location, Location: Reassessing Erythropoiesis Stimulating Agents (ESAs) in the United States (US), Canada, and Europe (2007-2011). <i>Blood</i> , 2011, 118, 4753-4753.	0.6	0
114	American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4996-5010.	0.8	257
115	Association Between Pharmaceutical Support and Basic Science Research on Erythropoiesis-Stimulating Agents. <i>Archives of Internal Medicine</i> , 2010, 170, 1490-8.	4.3	20
116	Hematologic Abnormalities Following Crotaline Snakebites In South Carolina. <i>Blood</i> , 2010, 116, 4753-4753.	0.6	1
117	Racial/Ethnic Disparities of Erythropoiesis Stimulating Agent Use Among the Insured Poor: Pre- and Post-Safety Advisories. <i>Blood</i> , 2010, 116, 395-395.	0.6	1
118	Finishing the Picture: Clopidogrel Is Indeed the Most Common Drug Associated with Thrombotic Thrombocytopenic Purpura (TTP) In FDA Databases: Its Mechanism, Laboratory Findings, Clinical Features, and Epidemiology Differ From That Associated with Ticlopidine. <i>Blood</i> , 2010, 116, 1527-1527.	0.6	0
119	Serious Adverse Drug Reactions (sADRS) Associated with Hematopoietic Growth Factors: A Systematic Review From the Southern Network on Adverse Reactions (SONAR) Program. <i>Blood</i> , 2010, 116, 2555-2555.	0.6	1
120	Reassessments of ESAs for cancer treatment in the US and Europe. <i>Oncology</i> , 2010, 24, 260-8.	0.4	11
121	Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Lancet Oncology</i> , The, 2009, 10, 816-824.	5.1	433
122	Progressive multifocal leucoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	0.6	829
123	Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.. <i>Blood</i> , 2009, 114, 4538-4538.	0.6	1
124	From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.. <i>Blood</i> , 2009, 114, 4555-4555.	0.6	0
125	Epoetin-associated pure red cell aplasia: past, present, and future considerations. <i>Transfusion</i> , 2008, 48, 1754-1762.	0.8	159
126	Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2008, 26, 132-149.	0.8	274



#	ARTICLE	IF	CITATIONS
127	Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA - Journal of the American Medical Association, 2008, 299, 914.	3.8	657
128	Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR). Blood, 2008, 112, 4662-4662.	0.6	0
129	Evaluation of Serious Adverse Drug Reactions. Archives of Internal Medicine, 2007, 167, 1041.	4.3	43
130	Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. Journal of Clinical Oncology, 2007, 25, 1596-1605.	0.8	507
131	Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. Journal of the National Cancer Institute, 2007, 99, 196-205.	3.0	260
132	Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura. Journal of the American College of Cardiology, 2007, 50, 1138-1143.	1.2	76
133	Long-term safety of filgrastim (rhG-CSF) administration: response to Confer & Miller and Bacher & Zander. British Journal of Haematology, 2007, 137, 79-80.	1.2	3
134	The value of innovation: the economics of targeted drugs for cancer. Targeted Oncology, 2007, 2, 113-119.	1.7	16
135	The Economics of Brain Metastases. Cancer Treatment and Research, 2007, 136, 23-29.	0.2	3
136	Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.. Blood, 2007, 110, 2088-2088.	0.6	3
137	Evaluating Mortality with Erythropoietic Stimulating Agents (ESAs) in the Nephrology Setting: The Distinction between Evaluating Trials That Measure Survival as a Primary or Secondary Efficacy Endpoint Versus a Safety Endpoint.. Blood, 2007, 110, 962-962.	0.6	15
138	Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.. Blood, 2007, 110, 3340-3340.	0.6	0
139	Treatment Success in Cancer.. Blood, 2007, 110, 631-631.	0.6	0
140	Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.. Blood, 2007, 110, 3339-3339.	0.6	0
141	Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.. Blood, 2007, 110, 2089-2089.	0.6	0
142	Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. JAMA - Journal of the American Medical Association, 2006, 296, 2555.	3.8	134
143	Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. British Journal of Haematology, 2006, 135, 642-650.	1.2	127
144	2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. Journal of Clinical Oncology, 2006, 24, 3187-3205.	0.8	1,530

#	ARTICLE	IF	CITATIONS
145	RADAR Update on Thalidomide (Thal)- and Lenalidomide (Len)-Associated Venous Thromboembolism (VTE): Safety Concerns Persist for Multiple Myeloma (MM) Despite FDA Approvals in This Setting.. Blood, 2006, 108, 3310-3310.	0.6	5
146	Inadvertent Intrathecal Administration of Vincristine.. Blood, 2006, 108, 3327-3327.	0.6	0
147	Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkin's Disease (HD), Indolent Non-Hodgkin's Lymphoma (INHL) and Aggressive Non-Hodgkin's Lymphoma (ANHL).. Blood, 2006, 108, 3332-3332.	0.6	0
148	Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood, 2005, 106, 3343-3347.	0.6	101
149	The Research on Adverse Drug Events and Reports (RADAR) Project. JAMA - Journal of the American Medical Association, 2005, 293, 2131.	3.8	111
150	The blue cross blue shield assessment technology review: summary of findings. Best Practice and Research in Clinical Haematology, 2005, 18, 423-431.	0.7	5
151	2005 Update on Accelerated FDA Approval of Drugs Used To Treat Hematologic Malignancies from the Research on Adverse Drug-Events and Reports (RADAR): Rate of Regular Approval Conversion Remains Low.. Blood, 2005, 106, 289-289.	0.6	1
152	Comparison of Out-of-Pocket Costs for Patients (pts) with Hodgkin's Disease (HD), Indolent Non-Hodgkin's Lymphoma (INHL) and Aggressive Non-Hodgkin's Lymphoma (ANHL).. Blood, 2005, 106, 2241-2241.	0.6	0
153	Incident TTP: Plasmapheresis Therapy-Related Complications Are Common.. Blood, 2005, 106, 1254-1254.	0.6	1
154	American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 2927-2941.	0.8	167
155	Pure Red-Cell Aplasia and Epoetin Therapy. New England Journal of Medicine, 2004, 351, 1403-1408.	13.9	398
156	Accelerated FDA Approval of Drugs Used To Treat Hematologic Malignancies: Are Policy Changes Needed?.. Blood, 2004, 104, 266-266.	0.6	5
157	Severe Gemcitabine-Associated Lung Injury in Hodgkins Disease & Other Cancers: Reporting Quality and Clinical Characteristics of Cases Reported in the Medical Literature and to the FDA.. Blood, 2004, 104, 3145-3145.	0.6	1
158	Long-Term Follow-Up of Recombinant Human Erythropoietin (epoetin)Induced Pure Red Cell Aplasia (PRCA): A Comparison of Data Collected through Active and Passive Pharmacovigilance Efforts.. Blood, 2004, 104, 5319-5319.	0.6	1
159	Subacute Thrombotic Events Associated with Drug Eluting Cardiac Stents May Be Localized Hypersensitivity Reactions to Polymers.. Blood, 2004, 104, 2198-2198.	0.6	0
160	Long-Term Follow-Up of 98 Cases of Recombinant Human Erythropoietin (epoetin) Induced Pure Red Cell Aplasia (PRCA): Outcomes and Treatment Data from the Research on Adverse Drug Reactions and Reports (RADAR) Program.. Blood, 2004, 104, 5320-5320.	0.6	0
161	Economic Analysis of Amifostine as Adjunctive Support for Patients with Advanced Head and Neck Cancer: Preliminary Results from a Randomized Phase II Clinical Trial from Germany. Cancer Investigation, 2001, 19, 107-113.	0.6	33
162	HIV-related Pneumocystis carinii pneumonia in older patients hospitalized in the early HAART era. Journal of General Internal Medicine, 2001, 16, 583-589.	1.3	10

#	ARTICLE	IF	CITATIONS
163	Changes in Finances, Insurance, Employment, and Lifestyle Among Persons Diagnosed with Hairy Cell Leukemia. <i>Oncologist</i> , 2001, 6, 435-440.	1.9	17
164	The Role of Inadequate Health Literacy Skills in Colorectal Cancer Screening. <i>Cancer Investigation</i> , 2001, 19, 193-200.	0.6	169
165	Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients. <i>Oncologist</i> , 2001, 6, 441-445.	1.9	98
166	Comparing Cost-Effectiveness Analyses for the Clinical Oncology Setting: The Example of the Gynecologic Oncology Group 111 Trial. <i>Cancer Investigation</i> , 2000, 18, 261-268.	0.6	3
167	Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine in the Setting of Coronary Artery Stents and Stroke Prevention. <i>Archives of Internal Medicine</i> , 1999, 159, 2524.	4.3	114
168	Cost Analysis of Second-Line Therapies for Platinum-Refractory Ovarian Cancer: Reimbursement Dilemmas for Medicare Patients. <i>Cancer Investigation</i> , 1999, 17, 559-565.	0.6	12
169	Health Economics in the Treatment of Colorectal Cancer. <i>Cancer Investigation</i> , 1998, 16, 582-587.	0.6	1
170	Cost-effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?. <i>Cancer</i> , 1996, 77, 1854-1861.	2.0	40
171	Cost-effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?. <i>Cancer</i> , 1996, 77, 1854-1861.	2.0	1
172	The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies. , 0, , 402-411.		0
173	Dauids versus Goliaths: Pharma and academia threats to individual scientists and clinicians. <i>The Journal of Scientific Practice and Integrity</i> , 0, , .	0.5	1